Skip to main content
SpringerLink
Log in
Book cover

Neoplastic Diseases of the Blood pp 985–1013Cite as

Diagnosis and Treatment of Hodgkin’s Lymphoma

  • Chapter
  • First Online:

  • 2732 Accesses

Abstract

The successful treatment of Hodgkin’s lymphoma is one of the most impressive achievements of modern medicine. Today more than 90 % of patients without fever, weight loss, or night sweats (B symptoms) are cured with optimal treatment, and 60–70 % of those with B symptoms are cured as well. Fortunately, most patients do not have B symptoms at presentation. These cure rates have not been achieved without problems. Long-term complications of cure have interrupted the well-being of a sizeable fraction of survivors, and relapses—even late relapses—are still a problem. Current clinical research is focused on optimal noninvasive staging of disease, reducing the short- and long-term complications of treatment, and early diagnosis of serious long-term complications such as cardiac disease and second malignancies.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   269.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin’s lymphoma microenvironment and its role in promoting tumor growth and immune escape. J Pathol. 2010;221:248.

    Article  PubMed  CAS  Google Scholar 

  2. Hjalgrim H, Rostgaard K, Johnson PC, et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin’s lymphoma. Proc Natl Acad Sci USA. 2010;107:6400.

    Article  PubMed  CAS  Google Scholar 

  3. Liu TY, Wu SJ, Huang MH, et al. EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis. Mol Cancer. 2010;9:9.

    Article  CAS  Google Scholar 

  4. Benharroch D, Einav I, Feldman A, et al. Apoptosis of Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma revisited. APMIS. 2010;118:339.

    Article  PubMed  Google Scholar 

  5. M’kacher R, Andreoletti L, Flamant S, et al. JC human polyomavirus is associated to chromosomal instability in peripheral blood lymphocytes of Hodgkin’ lymphoma patients and poor clinical outcome. Ann Oncol. 2010;21:826.

    Article  PubMed  Google Scholar 

  6. Knecht H, Sawan B, Lichtensztejn Z, et al. 3D telomere FISH defines LMP1-expressing Reed-Sternberg cells as end stage cells with telomere-poor “ghost” nuclei and very short telomeres. Lab Invest. 2010;90:61.

    Article  Google Scholar 

  7. Salipante SJ, Mealiffe ME, Wechsler J, et al. Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proc Natl Acad Sci USA. 2009;106:14920.

    Article  PubMed  CAS  Google Scholar 

  8. Krem MM, Salipante SJ, Horwitz MS. Mutations in a gene encoding a midbody protein in binucleated Reed-Sternberg cells of Hodgkin lymphoma. Cell Cycle. 2010;9:670.

    Article  PubMed  CAS  Google Scholar 

  9. Mollaki V, Georgiadis T, Tassidou A, et al. Polymorphisms and haplotypes in TLR8 and MYD88 are associated with development of Hodgkin’s lymphoma: a candidate-gene association study. J Hum Genet. 2009;54:655.

    Article  PubMed  CAS  Google Scholar 

  10. Sánchez-Espiridión B, Montalbán C, López A, et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood. 2010;116:e12.

    Article  PubMed  CAS  Google Scholar 

  11. Paietta E, Stockert RJ, Morell AG, et al. Unique antigen of cultured Hodgkin’s cells. A putative sialyltransferase. J Clin Invest. 1986;78:349.

    Article  PubMed  CAS  Google Scholar 

  12. Paietta E, Stockert RJ, Morell AG, et al. Lectin activity as a marker for Hodgkin disease cells. Proc Natl Acad Sci USA. 1986;83:3451.

    Article  PubMed  CAS  Google Scholar 

  13. Paietta E, Hubbard AL, Wiernik PH, Stockert RJ. Hodgkin’s cell lectin: an ectosialyltransferase and lymphocyte agglutinant related to the hepatic asialoglycoprotein receptor. Cancer Res. 1987; 47:246.

    Google Scholar 

  14. Paietta E, Stockert RJ, Morell AG, et al. A marker and putative pathoantigen of Hodgkin’s cells. Recent Results Cancer Res. 1989;117:91.

    Article  PubMed  CAS  Google Scholar 

  15. Athan ES, Paietta E, Papenhausen PR, et al. Stability of multiple antigen receptor gene rearrangements and immunophenotype in Hodgkin’s disease-derived cell line L428 and variant subline L428KSA. Leukemia. 1989;3:505.

    PubMed  CAS  Google Scholar 

  16. Paietta E, Stockert RJ, McManus M, et al. Hodgkin’s cell lectin: a lymphocyte adhesion molecule and mitogen. J Immunol. 1989;143:2850.

    PubMed  CAS  Google Scholar 

  17. Paietta E, Racevskis J, Stanley ER, et al. Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin’ disease-derived cell line and its variants. Cancer Res. 1990;50:2049.

    PubMed  CAS  Google Scholar 

  18. Mauch P, Gorshein D, Cunningham J, et al. Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin’s disease. Cancer Treat Rep. 1982;66:809.

    PubMed  CAS  Google Scholar 

  19. Mauch P, Tarbell N, Weinstein H, et al. Stage IA and IIA with supradiaphragmatic Hodgkin’s disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol. 1988;6:1576.

    PubMed  CAS  Google Scholar 

  20. Dahlqvist C, Betomvuko P, Verdebout JM, Mineur P. Immune thrombocytopenic purpura at the diagnosis of Hodgkin disease. Acta Clin Belg. 2010;65:41.

    PubMed  CAS  Google Scholar 

  21. Sissolak G, Sissolak D, Jacobs P. Human immunodeficiency and Hodgkin lymphoma. Transfus Apher Sci. 2010;42:131.

    Article  PubMed  Google Scholar 

  22. Alexandrescu DT, Garino A, Brown-Balem KA, Wiernik PH. Anticipation in families with Hodgkin’s and non-Hodgkin’s lymphoma in their pedigrees. Leuk Lymphoma. 2006;47:2115.

    Article  PubMed  Google Scholar 

  23. Kaplan HS. Hodgkin’s disease. 2nd ed. Cambridge: Harvard University Press; 1980.

    Google Scholar 

  24. Mauch P, Kalish L, Kadin M, et al. Pattern of presentation of Hodgkin’s disease. Implications for etiology and pathogenesis. Cancer. 1993;71:2062.

    Article  PubMed  CAS  Google Scholar 

  25. Kirschner RH, Abt AB, O’Connell MJ, et al. Vascular invasion and hematogenous dissemination of Hodgkin’s disease. Cancer. 1974;34:1159.

    Article  PubMed  CAS  Google Scholar 

  26. Ashigbi MY, Venkatraj U, Agarwal V, et al. Intracranial Hodgkin’s disease in two patients with familial Hodgkin’s disease. Med Pediatr Oncol. 1997;28:255.

    Article  PubMed  CAS  Google Scholar 

  27. Intrasco CE, Kantor J, Porter DL, Junkins-Hopkins JM. Cutaneous Hodgkin’s disease. J Am Acad Dermatol. 2008;58:295.

    Article  Google Scholar 

  28. Mullins GM, Lenhard Jr RE. Digital clubbing in Hodgkin’s disease. Johns Hopkins Med J. 1971;128:153.

    PubMed  CAS  Google Scholar 

  29. Atkinson MK, McElwain TJ, Peckham MJ, Thomas PP. Hypertrophic pulmonary osteoarthropathy in Hodgkin’s disease: reversal with chemotherapy. Cancer. 1976;38:1729.

    Article  PubMed  CAS  Google Scholar 

  30. Goodyer MJ, Cronin MC, Ketsitlile DG, et al. Hodgkin’s lymphoma with digital clubbing. J Clin Oncol. 2009;27:e95.

    Article  PubMed  Google Scholar 

  31. O’Connell MJ, Schimpff SC, Kirschner RH, et al. Epitheliod granulomas in Hodgkin disease. A favorable prognostic sign? JAMA. 1975;233:886.

    Article  PubMed  Google Scholar 

  32. Abt AB, Kirschner RH, Belliveau RE, et al. Hepatic pathology associated with Hodgkin’s disease. Cancer. 1974;33:1564.

    Article  PubMed  CAS  Google Scholar 

  33. Grogan TM, Berard CW, Steinhorn SC, et al. Changing patterns of Hodgkin’s disease at autopsy: a 25-year experience at the National Cancer Institute. 1975–1978. Cancer Treat Rep. 1982;66:653.

    PubMed  CAS  Google Scholar 

  34. Hasle H, Mellemgaard A. Hodgkin’s disease diagnosed post mortem: a population base study. Br J Cancer. 1993;67:185.

    Article  PubMed  CAS  Google Scholar 

  35. Provencio M, España P, Salas C, et al. Hodgkin’s disease: correlation between causes of death at autopsy and clinical diagnosis. Ann Oncol. 2000;11:59.

    Article  PubMed  CAS  Google Scholar 

  36. Jackson C, Sirohi B, Cunningham D, et al. Lymphocyte-predominant Hodgkin lymphoma-clinical features and treatment outcomes from a 30-year experience. Ann Oncol. 2010; 21(10):2061.

    Article  PubMed  CAS  Google Scholar 

  37. Maeda LS, Advani RH. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol. 2009;21:397.

    Article  PubMed  CAS  Google Scholar 

  38. Bodis S, Henry-Amar M, Bosq J. Late relapse in early-stage Hodgkin’s disease patients enrolled in the European Organization for Research and Treatment of Cancer Protocols. J Clin Oncol. 1993;11:225.

    PubMed  CAS  Google Scholar 

  39. Salvagno L, Sorarù M, Aversa SML, et al. Late relapses in Hodgkin’s disease: outcome of patients relapsing more than twelve months after primary chemotherapy. Ann Oncol. 1993; 4:657.

    PubMed  CAS  Google Scholar 

  40. Roach M, Brophy N, Cox R, et al. Prognostic factors for patients relapsing after radiotherapy for early stage Hodgkin’s disease. J Clin Oncol. 1990;8:623.

    PubMed  Google Scholar 

  41. Longo DL, Duffey PL, Young RC, et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination: the low probability for cure. J Clin Oncol. 1992;10:210.

    PubMed  CAS  Google Scholar 

  42. Lee KM, Spittle MF. Hodgkin’s disease: a case of late relapse. Clin Oncol (R Coll Radiol). 1993;5:399.

    Article  CAS  Google Scholar 

  43. Mihaljevic BS, Jovanovic LR, Sretenovic AM, Boskovic DV. Hodgkin’s lymphoma relapse in the uterine cervix 15 years after the initial cure. Med Oncol. 2008;25:245.

    Article  PubMed  Google Scholar 

  44. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphoma. Summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112.

    Article  Google Scholar 

  45. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation of staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1990; 8:1602.

    Google Scholar 

  46. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506.

    Article  PubMed  CAS  Google Scholar 

  47. Harris NL, Jaffe ES, Stein H, et al. A revised European-American lymphoma classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361.

    PubMed  CAS  Google Scholar 

  48. Brice P. Prognostic factors in advanced Hodgkin’s disease – can they guide therapeutic decisions? N Engl J Med. 1998;339:1547.

    Article  PubMed  CAS  Google Scholar 

  49. Pera A. Lymphangiography and CT in the follow-up of patients with lymphoma. Radiology. 1987;164:131.

    Google Scholar 

  50. Castellino RA, Hoppe RT, Blank N, et al. Computed tomography, lymphangiography and staging laparotomy: correlations in initial staging of Hodgkin’s disease. Am J Radiol. 1984;143:37.

    CAS  Google Scholar 

  51. Mansfield CM, Fabian C, Jones S, et al. Comparison of lymphangiography and computed tomography scanning in evaluating abdominal disease in stage III and IV Hodgkin’s disease. Cancer. 1988;66:229.

    Google Scholar 

  52. Musumeci R, Tesoro-Tess JD. New imaging techniques in staging lymphomas. Curr Opin Oncol. 1994;21:464.

    Article  Google Scholar 

  53. Dann EJ, Bar-Shalom R, Tamir A, et al. A functional dynamic scoring model to elucidate the significance of post-induction interim F18FDC-PET/CT scanning in patients with Hodgkin lymphoma. Haematologica. 2010;95:1198.

    Article  PubMed  Google Scholar 

  54. Pommier P, Dussart S, Girinsky T, et al. Impact of 18 F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study. Int Radiat Biol Phys. 2011;79(3):823–8.

    Article  Google Scholar 

  55. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824–33.

    Article  PubMed  Google Scholar 

  56. Ahmadzadehfar H, Rodrigues M, Zakavi R, et al. Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma. Med Oncol. 2011;28(4):1570–6.

    Article  PubMed  CAS  Google Scholar 

  57. Radford JA, Cowan RA, Flanagan M, et al. The significance of residual mediastinal abnormality in chest radiograph following treatment for Hodgkin’s disease. J Clin Oncol. 1988;6:940.

    PubMed  CAS  Google Scholar 

  58. Jochelson M, Mauch P, Balikian J, et al. The significance of the residual mediastinal mass in treated Hodgkin’s disease. J Clin Oncol. 1985;3:637.

    PubMed  CAS  Google Scholar 

  59. Devizzi L, Balzarini L, Santoro A, et al. Comparison of gallium scan, computed tomography and magnetic resonance in patients with mediastinal Hodgkin’s disease. Ann Oncol. 1997;8 Suppl 1:53.

    Article  PubMed  Google Scholar 

  60. Stumpe KD, Urbnelli M, Steinert HC, Glanzmann C, Buk A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med. 1998;25:721.

    Article  PubMed  CAS  Google Scholar 

  61. Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin’s disease results in a high false positive rate. J Pediatr Hematol Oncol. 2007;29:66707.

    Article  Google Scholar 

  62. Tubiana M, Henry-Amar M, Carde P, et al. Towards comprehensive management tailored to prognostic factors of patients with clinical stage I and II Hodgkin’s disease. The EORTC Lymphoma group controlled clinical trials: 1964–1987. Blood. 1989;73:47.

    PubMed  CAS  Google Scholar 

  63. O’Connell MJ, Wiernik PH, Sklansky BD, et al. Staging laparotomy in Hodgkin’s disease further evidence in support of its clinical utility. Am J Med. 1974;57:86.

    Article  PubMed  Google Scholar 

  64. Lee AJ, Zuckerman DS, den Abbeele Van, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer. 2010;116(16):3835–42.

    Article  PubMed  Google Scholar 

  65. Mocikova H, Obrtikova P, Vackova B, Trmeny M. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol. 2010;16:1222.

    Article  Google Scholar 

  66. Furth C, Steffen IG, Amthauer H, et al. Early and late therapy response assessment with [18 F] fluorodeoxyglucose positron emission tomography in pediatric Hodgkin’s lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009;27:4385.

    Article  PubMed  Google Scholar 

  67. Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin’s disease. J Clin Oncol. 1998;16: 536–44.

    PubMed  CAS  Google Scholar 

  68. Aisenberg AC, Finkelstein DM, Doppke KP, et al. High risk of breast carcinoma after irradiation of young women with Hodgkin’s disease. Cancer. 1997;79:1203.

    Article  PubMed  CAS  Google Scholar 

  69. Kaplan HS. Hodgkin’s disease: biology, treatment and prognosis. Blood. 1982;57:813.

    Google Scholar 

  70. Diehl V, Mauch PM, Harris NL. Hodgkin’s disease. In: Cancer principles and practice of oncology. 6th ed. Philadelphia: Lippincott; 2001.

    Google Scholar 

  71. Aisenberg AC. Problems in Hodgkin’s disease management. Blood. 1999;93:761.

    PubMed  CAS  Google Scholar 

  72. Cosset JM, Henry-Amar M, Noordijk EM, et al. The EORTC trials for adult patients with early stage Hodgkin’s disease. A 1997 update. ASTRO Lymphoma Categorical Course. Reston: VA; 1997.

    Google Scholar 

  73. Radford JA, Cowan RA, Ryder WDJ, et al. Four weeks of neo-adjuvant chemotherapy significantly reduces the progression rate in patients treated with limited field radiotherapy for clinical stage IA/IIA Hodgkin’s disease. Results of a randomised pilot study. Ann Oncol. 1996;7 Suppl 3:666.

    Google Scholar 

  74. Horning SJ, Hoppe RT, Mason J, et al. Stanford-Kaiser Permanente G1 study for clinical stage I to II Hodgkin’s disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol. 1997; 15:1736.

    PubMed  CAS  Google Scholar 

  75. Specht L, Gray R, Clarke M, et al. The influence of more extensive radiotherapy and adjuvant chemotherapy on long term outcome of early stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3888 patients. J Clin Oncol. 1988;16:830.

    Google Scholar 

  76. Devita Jr VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73:881.

    PubMed  Google Scholar 

  77. Santoro A, Bonadonna G. Prolonged disease free survival in MOPP-resistant Hodgkin’s disease after treatment with Adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol. 1979;2:101.

    Article  PubMed  CAS  Google Scholar 

  78. Bonadonna G. Modern treatment of malignant lymphomas: a multidisciplinary approach? Ann Oncol. 1994;5:85.

    Google Scholar 

  79. Bonadonna G, Valagussa P, Santoro A. Alternating non cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med. 1986;104:739.

    PubMed  CAS  Google Scholar 

  80. Santoro A, Bonadonna G, Bonfante V, et al. Alternating drug combination in the treatment of advanced Hodgkin’s disease. N Engl J Med. 1982;306:770.

    Article  PubMed  CAS  Google Scholar 

  81. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987;5:27.

    PubMed  CAS  Google Scholar 

  82. Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin’s disease. Ann Intern Med. 1982;96:139.

    PubMed  CAS  Google Scholar 

  83. Goldie JH, Coldman JA. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727.

    PubMed  CAS  Google Scholar 

  84. Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin’s disease with chemotherapy. Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1997;15:1638.

    PubMed  CAS  Google Scholar 

  85. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten year results. J Clin Oncol. 1996;14:1421.

    PubMed  CAS  Google Scholar 

  86. Glick JH, Young ML, Harringhton D, et al. MOPP/ABVD hybrid chemotherapy for advanced Hodgkin’s disease significantly improves failure-free and overall survival: the 8 year results of the intergroup trial. J Clin Oncol. 1998;16:19.

    PubMed  CAS  Google Scholar 

  87. Canellos JP, Anderson J, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478.

    Article  PubMed  CAS  Google Scholar 

  88. Tesch H, Diehl V, Lathan B, et al. Moderate dose escalation for advanced stage Hodgkin’s disease using the bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin’s lymphoma study group. Blood. 1998;92:4560.

    PubMed  CAS  Google Scholar 

  89. Diehl V, Franklin J, Hasenclever D, et al. BEACOPP a new dose escalated and accelerated regimen is a least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s lymphoma study group. J Clin Oncol. 1998;16:3810.

    PubMed  CAS  Google Scholar 

  90. Edwards-Bennett SM, Jacks LM, Moskowitz CH, et al. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol. 2009;21:574.

    Article  PubMed  Google Scholar 

  91. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin’s lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group study ISRCTN 64141244. J Clin Oncol. 2009;27:5390.

    Article  PubMed  Google Scholar 

  92. Gobbi PG, Pierasca C, Ghirardelli ML, et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin’s disease. Blood. 1998;91:2704.

    PubMed  CAS  Google Scholar 

  93. Lancet JE, Rapoport AP, Brasacchio R, et al. Autotransplantation for relapsed or refractory Hodgkin’s disease: Long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant. 1998;22:265.

    Article  PubMed  CAS  Google Scholar 

  94. Akhtar S, Weshi A, Rahal M, et al. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin’s lymphoma. Bone Marrow Transplant. 2010;45:476.

    Article  PubMed  CAS  Google Scholar 

  95. Shafer JA, Heslop HE, Brenner MK, et al. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin’s lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010;51:664.

    Article  PubMed  CAS  Google Scholar 

  96. Majhail NS, Bajorunaite R, Lazarus HM, et al. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol. 2009;147:129.

    Article  PubMed  Google Scholar 

  97. Vivani S, Di Nicola M, Bonfante V, et al. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymphoma. 2010;51:1251.

    Article  CAS  Google Scholar 

  98. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomized trial. Lancet. 1993;341:1051.

    Article  PubMed  CAS  Google Scholar 

  99. Claviez A, Canals C, Dierickx D, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood. 2009;114:2060.

    Article  PubMed  CAS  Google Scholar 

  100. Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol. 1996;14:572.

    PubMed  CAS  Google Scholar 

  101. Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115:3671.

    Article  PubMed  CAS  Google Scholar 

  102. Wiernik PH, Gustafson J, Schimpff SC, Diggs C. Combined modality treatment of Hodgkin’s disease confined to lymph nodes results eight years later. Am J Med. 1979;67:183.

    Article  PubMed  CAS  Google Scholar 

  103. Longo DL, Glatstein E, Duffey PL, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin’s disease: seven-year results of a prospective randomized trial. J Clin Oncol. 1991;9:906.

    PubMed  CAS  Google Scholar 

  104. Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010;28:1611.

    Article  PubMed  Google Scholar 

  105. O’Dwyer PJ, Wiernik PH, Stewart MB, Slawson RG. Treatment of early stage Hodgkin’s disease: a randomised trial of radiotherapy plus chemotherapy versus chemotherapy alone. In: Cavalli F, Bonadonna G, Rozencweig M, et al., editors. Malignant lymphoma and Hodgkin’s disease: experimental and therapeutic advances. Leiden: Martinus Nijhoff; 1985. p. 329.

    Chapter  Google Scholar 

  106. Pavlovsky S, Dupont J, Jimenez E, et al. Randomized study of chemotherapy alone vs. chemotherapy plus radiotherapy in clinical stage IA-IIA Hodgkin’s disease. In: Cavalli F, Bonadonna G, Rozencweig M, et al., editors. Malignant lymphoma and Hodgkin’s disease: experimental and therapeutic advances. Leiden: Martinus Nijhoff; 1985. p. 337.

    Chapter  Google Scholar 

  107. Wiernik PH, Hong F, Glick JH, Bnnett JM. Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study of the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up. Leuk Lymphoma. 2009;50:1632.

    Article  PubMed  CAS  Google Scholar 

  108. Wiernik PH, Slawson RG. Hodgkin’s disease with direct extension into pulmonary parenchyma from a mediastinal mass: a presentation requiring special therapeutic considerations. Cancer Treat Rep. 1982;66:711.

    PubMed  CAS  Google Scholar 

  109. Dominguez R, Márquez A, Gumá J, et al. Treatment of stage I and II Hodgkin’s lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol. 2004;15:1798.

    Article  Google Scholar 

  110. Olcese F, Clavio M, Rossi E, et al. The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin’s lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. Ann Hematol. 2009;88:855.

    Article  PubMed  Google Scholar 

  111. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993;11:2258.

    PubMed  CAS  Google Scholar 

  112. Prosnitz LR, Farber LR, Kapp DS, et al. Combined modality therapy for advanced Hodgkin’s disease: 15-year follow-up data. J Clin Oncol. 1988;6:603.

    PubMed  CAS  Google Scholar 

  113. Yelle L, Bergsagel D, Basco V, et al. Combined modality therapy of Hodgkin’s disease: ten-year results of National Cancer Institute of Canada Clinical Trials Group Multicenter Clinical Trial. J Clin Oncol. 1991;9:1983.

    PubMed  CAS  Google Scholar 

  114. Viviani S, Santoro A, Negretti E, et al. Salvage chemotherapy in Hodgkin’s disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol. 1990;1:123.

    PubMed  CAS  Google Scholar 

  115. Rosenberg SA. Reducing the toxicity of the combined modality therapy of favourable–stage Hodgkin’s disease. Eur J Cancer. 1992;28A:1379.

    Article  PubMed  CAS  Google Scholar 

  116. Zagars G, Rubin P. Hodgkin’s disease stage IA-IIA: a long-term follow-up study on the results achieved by modern therapy. Cancer. 1986;56:1907.

    Google Scholar 

  117. Carde P, Burgers JMV, Henry-Amar M, et al. Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol. 1988;6:239.

    PubMed  CAS  Google Scholar 

  118. Rosenberg SA, Kaplan HS. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin’s disease, 1962–1984. Int J Radiat Biol Phys. 1985;11:5.

    Article  CAS  Google Scholar 

  119. Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I–II Hodgkin’s disease. J Natl Cancer Inst. 1988;80:14668.

    Article  Google Scholar 

  120. Radford JA, Rohatiner AZ, Ryder WD, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol. 2002;20:2988.

    Article  PubMed  CAS  Google Scholar 

  121. Horning SJ, Hoppe RT, Hancock SL, et al. Vinblastine, bleomycin and methotrexate: an effective adjuvant in favorable Hodgkin’s disease. J Clin Oncol. 1988;6:1822.

    PubMed  CAS  Google Scholar 

  122. Santoro A, Bonfante V, Viviani S. Subtotal nodal (STNI) vs involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin’s disease (HD). Proc Am Soc Clin Oncol. 1996;15:415 (A).

    Google Scholar 

  123. Biti GP, Cimino C, Cartoni C, et al. Extended-field radiotherapy is superior to MOPP chemotherapy in the treatment of pathologic stage IA–IIA Hodgkin’s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol. 1991;9:906.

    Google Scholar 

  124. Macdonald DA, Ding K, Gospardarowicz MK, et al. Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol. 2007;18:1680.

    Article  PubMed  CAS  Google Scholar 

  125. Bonfante V, Santoro A, Viviani S, et al. Early stage Hodgkin’s disease: ten-year results of a non-randomized study with radiotherapy alone or combined with MOPP. Eur J Cancer. 1992;29A:24.

    PubMed  CAS  Google Scholar 

  126. Specht L, Gray R, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long term outcome of early stage Hodgkin’s disease: a metanalysis of 23 randomized trials involving 3888 patients. J Clin Oncol. 1988;16:830.

    Google Scholar 

  127. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International database on Hodgkin’s disease overview study group. J Clin Oncol. 1999;16:818.

    Google Scholar 

  128. Armitage JO. Early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363:653.

    Article  PubMed  CAS  Google Scholar 

  129. Chen RG, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010;28:136.

    Article  PubMed  Google Scholar 

  130. Jackson C, Sirohi B, Cunningham D, et al. Lymphocyte-predominant Hodgkin lymphoma-clinical features and treatment outcomes from a 30-year experience. Ann Oncol. 2010;21(10):2061–8.

    Article  PubMed  CAS  Google Scholar 

  131. Longo DL, Young RC, Wesly M, et al. Twenty years of MOPP chemotherapy for Hodgkin’s disease. J Clin Oncol. 1986;4:1295.

    PubMed  CAS  Google Scholar 

  132. Hodgson DC, Pintile M, Yun R, et al. Clinically significantly delayed cardiac morbidity following ABVD chemotherapy for Hodgkin lymphoma: a population-based study. J Clin Oncol. 2010;28(15s). Abstract 8059.

    Google Scholar 

  133. Valagussa P, Bonadonna G, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin’s disease. J Clin Oncol. 1986;4:830.

    PubMed  CAS  Google Scholar 

  134. Canellos JP. Is ABVD the standard regimen for Hodgkin’s disease based on randomized CALGB comparison of MOPP, ABVD, and MOPP alternating with ABVD? Leukemia. 1996;10 Suppl 2:S68.

    PubMed  Google Scholar 

  135. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548.

    Article  PubMed  Google Scholar 

  136. Halbsguth TV, Nogová L, Mueller H, et al. Phase II study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2010;116(12):2026–32.

    Article  PubMed  CAS  Google Scholar 

  137. Gianni AM, Rambaldi A, Zinzani P et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized of the Michelangelo, GITL and IIL cooperative groups. J Clin Oncol 2008; 26(Suppl): abstract 8506.

    Google Scholar 

  138. Eich HT, Gossmann A, Engert A, et al. A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin’s lymphoma-analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys. 2007;69:1187.

    Article  PubMed  Google Scholar 

  139. Viviani S, Bonfante V, Santoro A, et al. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin’s disease. Cancer J Sci Am. 2000;5:275.

    Google Scholar 

  140. Alexandrescu DT, Karri S, Wiernik PH, Dutcher JP. Mitoxantrone, vinblastine, and CCNU: long-term follow-up of patients treated for advanced and poor prognosis Hodgkin’s disease. Leuk Lymphoma. 2006;47:641.

    Article  PubMed  CAS  Google Scholar 

  141. Carella AM, Prencipe E, Pungolino E, et al. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high risk Hodgkin’s disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymphoma. 1996;21:63.

    Article  PubMed  CAS  Google Scholar 

  142. Delain M, Cartron G, Bout M, et al. Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin’s disease and analysis of predictive factors of outcome. Leuk Lymphoma. 1999;34:305.

    PubMed  CAS  Google Scholar 

  143. Nademanee A, Molina A, Fung H, et al. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin’s disease during first partial or complete remission. Biol Blood Marrow Transplant. 1999; 5:292.

    Article  PubMed  CAS  Google Scholar 

  144. Frei III E, Luce JK, Gamble G, et al. Combination chemotherapy in advanced Hodgkin’s disease: induction and maintenance of remission. Ann Intern Med. 1973;79:376.

    PubMed  Google Scholar 

  145. Young RC, Canellos GP, Chabner BA, et al. Patterns of relapse in advanced Hodgkin’s disease. Cancer. 1978;42:1001.

    Article  PubMed  CAS  Google Scholar 

  146. Longo DL. The case against the routine use of radiation therapy in advanced stage Hodgkin’s disease. Cancer Invest. 1996;14:353.

    Article  PubMed  CAS  Google Scholar 

  147. Prosnitz LR, Wu JJ, Yahalom J. The case for adjuvant radiation therapy in advanced stage Hodgkin’s disease. Cancer Invest. 1996;14:361.

    Article  PubMed  CAS  Google Scholar 

  148. Mauch PM. Controversies in the management of early stage Hodgkin’s disease. Blood. 1994;83:319.

    Google Scholar 

  149. Hoppe RT. Radiation therapy as a component of high-dose salvage strategies in Hodgkin’s disease. Ann Oncol. 1999;9 Suppl 5:87.

    Google Scholar 

  150. Wu JJ, Prosnitz LR. The role of adjuvant radiation therapy for stage III and IV Hodgkin’s disease. Semin Radiat Oncol. 1996;6:196.

    Article  PubMed  Google Scholar 

  151. Yahalom J, Ryu J, Straus DJ, et al. Impact of adjuvant radiation on the pattern and rate of relapse in advanced stage Hodgkin’s disease treated with alternating chemotherapy combinations. J Clin Oncol. 1991;9:2193.

    PubMed  CAS  Google Scholar 

  152. Loeffler M, Diehl V, Pfreundschuh M. for the German Hodgkin’s Lymphoma Study Group. Dose–response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin’s disease. J Clin Oncol. 1997;15:2275.

    PubMed  CAS  Google Scholar 

  153. Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved-field radiation after chemotherapy in advanced Hodgkin’s disease. Ann Intern Med. 1994;120:903.

    PubMed  CAS  Google Scholar 

  154. Fermé C, Sebban C, Hennequin C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease: results of the Groupe d’Études des Lymphomes de l’Adulte H89 trial. Blood. 2000;95:2246.

    PubMed  Google Scholar 

  155. Bonadonna G. Salvage treatments in Hodgkin’s disease. Eur J Cancer. 1991;27:530.

    Article  PubMed  CAS  Google Scholar 

  156. Canellos GP. Is there an effective salvage regimen for advanced Hodgkin’s disease? Ann Oncol. 1991;2:1.

    PubMed  Google Scholar 

  157. Bonadonna G, Santoro A, Gianni AM, et al. Primary and salvage chemotherapy in advanced Hodgkin’s disease. The Milan Centre Institute experience. Ann Oncol. 1991;1 Suppl 1:9.

    Google Scholar 

  158. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol. 1997;15:528.

    PubMed  CAS  Google Scholar 

  159. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89:801.

    PubMed  CAS  Google Scholar 

  160. Yuen AR, Horning SJ. Hodgkin’s disease: management of first relapse. Oncology. 1996;10:233.

    PubMed  CAS  Google Scholar 

  161. Bodis S, Henry-Amar M, Bosq J, et al. Late relapse in early stage Hodgkin’s disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J Clin Oncol. 1993;11:225.

    PubMed  CAS  Google Scholar 

  162. Bonadonna G, Santoro AM, Gianni AM, et al. Primary and salvage chemotherapy in advanced Hodgkin’s disease: the Milan Cancer Institute experience. Ann Oncol. 1991;1:9.

    Google Scholar 

  163. Santoro A, Viviani S, Valagussa P, et al. CCNU, etoposide and prednimustine (CEP) in refractory Hodgkin’s disease. Semin Oncol. 1986;13 Suppl 1:23.

    PubMed  CAS  Google Scholar 

  164. Pfreundschuh MG, Schoppe WD, Fuchs R, et al. Lomustine, etoposide, vindesine and dexamethasone (CEVD) in Hodgkin’s lymphoma refractory to cyclophosphamide, vincristine, procarbazine and prednisone (COPP) and doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD): a multicenter trial of the German Hodgkin’s Lymphoma Study Group. Cancer Treat Rep. 1987;71:1203.

    PubMed  CAS  Google Scholar 

  165. Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients. Cancer. 1996;78:1293.

    Article  PubMed  CAS  Google Scholar 

  166. Bonfante V, Viviani S, Santoro A, et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin’s disease. Br J Haematol. 1998;103 Suppl 2:533.

    Article  PubMed  CAS  Google Scholar 

  167. Fermé C, Bastion Y, Lepage E, et al. MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann Oncol. 1995;6:517.

    Google Scholar 

  168. Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine in the treatment of refractory Hodgkin’s disease. Ann Oncol. 1994;5:817.

    PubMed  CAS  Google Scholar 

  169. Chopra R, McMillian AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood. 1993;81:1137.

    PubMed  CAS  Google Scholar 

  170. Bierman PJ, Anderson JR, Freeman MB, et al. High dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin’s disease patients following first relapse after chemotherapy. Ann Oncol. 1996;7:151.

    Article  PubMed  CAS  Google Scholar 

  171. Reece DE, Connors JM, Spinelli JJ, et al. Intensive chemotherapy with cyclophosphamide, carmustine, etoposide +/− cisplatin and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood. 1994;83:1193.

    PubMed  CAS  Google Scholar 

  172. Wheeler C, Eickhoff C, Elias A, et al. High-dose cyclophosphamide, carmustine and etoposide with autologous transplantation in Hodgkin’s disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997;3:98.

    PubMed  CAS  Google Scholar 

  173. Sweetenham JW, Taghipour G, Milligan D, et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT. Bone Marrow Transplant. 1997;20:745.

    Article  PubMed  CAS  Google Scholar 

  174. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival for high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French Registry. Bone Marrow Transplant. 1997;20:21.

    Article  PubMed  CAS  Google Scholar 

  175. Gianni AM, Siena S, Bregni M, et al. High dose sequential chemoradiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin’s disease. Ann Oncol. 1993;4:889.

    PubMed  CAS  Google Scholar 

  176. Reece DE, Barnett MJ, Shepherd JD, et al. High dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/−P) and autologous transplantation for patients with Hodgkin’s disease who fail to enter a complete remission after combination chemotherapy. Blood. 1995;86:451.

    PubMed  CAS  Google Scholar 

  177. Prince HM, Crump M, Imrie K, et al. Intensive therapy and auto-transplant for patients with an incomplete response to front line therapy for lymphoma. Ann Oncol. 1996;7:1043.

    Article  PubMed  CAS  Google Scholar 

  178. Lazarus HM, Rowlings PA, Zhang MJ, et al. Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999;17:534.

    PubMed  CAS  Google Scholar 

  179. Brice P, Divine M, Simon D, et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavourable (UF) relapse from Hodgkin’s disease (HD). Ann Oncol. 1999;10:1485.

    Article  PubMed  CAS  Google Scholar 

  180. Canellos GP. Treatment of relapsed Hodgkin’s disease: strategies and prognostic factors. Ann Oncol. 1998;9 Suppl 5:S91–6.

    Article  PubMed  Google Scholar 

  181. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012; in press.

    Article  PubMed  CAS  Google Scholar 

  182. Santoro A, Bredenfield H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of multicenter phase II study. J Clin Oncol. 2000;18:2615.

    PubMed  CAS  Google Scholar 

  183. Josting A, Kàtay I, Rueffer U, et al. Favourable outcome of patients with relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol. 1998;9:289.

    Article  PubMed  CAS  Google Scholar 

  184. Weaver CH, Zhen B, Buckner CD. Treatment of patients with malignant lymphoma with mini-BEAM reduces the yield of CD34+ peripheral blood stem cells. Bone Marrow Transplant. 1998;21:1169.

    Article  PubMed  CAS  Google Scholar 

  185. Ribrag V, Nasr F, Bouhris JH, et al. VIP (etoposide, ifosfamide and cisplatin) as a salvage intensification program in relapsed or refractory Hodgkin’s disease. Bone Marrow Transplant. 1998;21:969.

    Article  PubMed  CAS  Google Scholar 

  186. Arai S, Letsunger R, Wong RM, et al. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2010;16:1145.

    Article  PubMed  CAS  Google Scholar 

  187. Schnell R, Vitetta E, Schindler J, et al. Treatment of refractory Hodgkin’s lymphoma patients with an anti-CD25 ricin a-chain immunotoxin. Leukemia. 2000;14:129.

    Article  PubMed  CAS  Google Scholar 

  188. Tsimberidou AM, O’Brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M.D. Anderson Cancer Center experience. Cancer. 2006;107:1294.

    Article  PubMed  CAS  Google Scholar 

  189. Adiga GU, Abebe L, Wiernik PH. Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin’s disease: case report and literature review. Am J Hematol. 2003;72:267.

    Article  PubMed  Google Scholar 

  190. Fong D, Kaiser A, Spizzo G, et al. Hodgkin’s disease variant Richter’s syndrome in chronic lymphocytic leukemia patients previously treated with fludarabine. Br J Haematol. 2005;129:199.

    Article  PubMed  Google Scholar 

  191. Dujardin F, Lefrancq T, Blẻchet C, et al. Hodgkin’s disease variant of Richter’s syndrome: two cases and literature review. Ann Pathol. 2008;28:311.

    Article  PubMed  Google Scholar 

  192. Robak T, Szmigielska-Kaplon A, Smolewski P, et al. Hodgkin’s type Richter’s syndrome in familial chronic lymphocytic leukemia treated with cladribine and cyclophosphamide. Leuk Lymphoma. 2003;44:859.

    Article  PubMed  CAS  Google Scholar 

  193. Tzankov A, Fong D. Hodgkin’s disease variant of Richter’s syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL. Med Hypotheses. 2006;66:577.

    Article  PubMed  CAS  Google Scholar 

  194. Tarrand JJ, Keating MJ, Tsimberidou AM, et al. Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer. 2010;116:880.

    Article  PubMed  CAS  Google Scholar 

  195. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270:1949.

    Article  PubMed  CAS  Google Scholar 

  196. Loge JH, Abrahamsen AF, Ekeberg O, et al. Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol. 1999;17:253.

    PubMed  CAS  Google Scholar 

  197. Glanzmann C, Kaufmann P, Jenni R, et al. Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol. 1998;46:51.

    Article  PubMed  CAS  Google Scholar 

  198. Myrehaug S, Pintilie M, Yun L, et al. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with pre-existing heart disease. Blood. 2010;116(13):2237–40.

    Article  PubMed  CAS  Google Scholar 

  199. Andersen R, Wethal T, Günther A, et al. Relation of coronary artery calcium score to premature coronary artery disease in survivors >15 years of Hodgkin’s lymphoma. Am J Cardiol. 2010;105:149.

    Article  PubMed  Google Scholar 

  200. Appelfeld MM, Slawson RG, Hall-Craigs M, et al. Delayed pericardial disease after radiotherapy. Am J Cardiol. 1981;47:210.

    Article  Google Scholar 

  201. Sandoval C, Pui CH, Bowman LC, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol. 1993;11:1039.

    PubMed  CAS  Google Scholar 

  202. Schonfeld SJ, Gilbert ES, Dores GM, et al. Acute myeloid leukemia following Hodgkin lymphoma: a population-base study of 35,511 patients. J Natl Cancer Inst. 2006;98:215.

    Article  PubMed  Google Scholar 

  203. Abratt RP, Morgan GW, Silvestri G, Wilcox P. Pulmonary complications of radiation therapy. Clin Chest Med. 2004;25:167.

    Article  PubMed  Google Scholar 

  204. Buchier T, Bomanji J, Lee SM. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin’s disease–a useful tool for monitoring pulmonary toxicity and disease activity. Haematologica. 2007;92:e120.

    Article  Google Scholar 

  205. Hirsch A, Els NV, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early stage Hodgkin’s disease. J Clin Oncol. 1994;219:615.

    Google Scholar 

  206. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614.

    Article  PubMed  CAS  Google Scholar 

  207. Macann A, Bredenfeld H, Moller RP, et al. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin’s lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin’s Lymphoma Study Group. Int J Radiat Oncol Biol Phys. 2008;70:161.

    Article  PubMed  CAS  Google Scholar 

  208. Iqbal U, Radhakrishnan N, Kaufman M et al. Bleomycin dose modification in Hodgkin disease (HD) treated with ABVD: Patient characteristics, treatment outcomes, and association with mixed cellularity (MC) histology. J Clin Oncol. 2007;25 (18S):18525 Abstract.

    Google Scholar 

  209. Villani F, Busia A, Villani M, et al. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin’s disease. Anticancer Res. 2009;29:777.

    PubMed  CAS  Google Scholar 

  210. Lorenzo Y, Provencio M, Lombardia L, et al. Differential genetic and functional markers of second neoplasias in Hodgkin’s disease patients. Clin Cancer Res. 2009;15:4823.

    Article  PubMed  CAS  Google Scholar 

  211. Andersson A, Enblad G, Tavelin B, et al. Family history of cancer as a risk factor for second malignancies after Hodgkin’s lymphoma. Br J Cancer. 2008;98:1001.

    Article  PubMed  CAS  Google Scholar 

  212. Brusamolino E, Baio A, Orlandi E, et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin’s lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res. 2006;12:6487.

    Article  PubMed  CAS  Google Scholar 

  213. Avers SM, Trentin C, Sorarű M, et al. Acute promyelocytic leukemia after Stanford V plus radiotherapy for advanced Hodgkin lymphoma. Leuk Lymphoma. 2009;50:1214.

    Article  CAS  Google Scholar 

  214. Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other second malignancies following treatment for Hodgkin’s disease. J Clin Oncol. 1986;3:830.

    Google Scholar 

  215. Pedersen-Bjergaard J, Larsen SO. Incidence of acute non-lymphocytic leukemia, preleukemia and myeloproliferative syndrome up to ten years after treatment of Hodgkin’s disease. N Engl J Med. 1982;307:965.

    Article  PubMed  CAS  Google Scholar 

  216. Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol. 1992;3:107.

    PubMed  CAS  Google Scholar 

  217. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol. 1998;124:207–14.

    Article  PubMed  CAS  Google Scholar 

  218. Sobecks RM, Le Beau MM, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23:1161–5.

    Article  PubMed  CAS  Google Scholar 

  219. Forrest DL, Hogge DE, Nevill TJ, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin’s lymphoma: a comparison of conventional therapy with Hodgkin’s lymphoma: a comparison of conventional therapy alone versus conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol. 2005;23:7994.

    Article  PubMed  CAS  Google Scholar 

  220. Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of a64 patients from the Adult Lymphoma Study Group. Cancer. 2010;116:631.

    Article  PubMed  Google Scholar 

  221. Swerdlow AJ, Shoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin’s disease: a nested case–control study of the relation to treatment. J Clin Oncol. 2001;19:1610.

    PubMed  CAS  Google Scholar 

  222. Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin’s lymphoma: a systematic review. Lancet Oncol. 2005;6:773.

    Article  PubMed  Google Scholar 

  223. Konits PH, Aisner J, Whitacre M, Wiernik PH. Lung cancer as a complication of prolonged survival in patients with lymphoma. Med Pediatr Oncol. 1982;10:331.

    Article  PubMed  CAS  Google Scholar 

  224. Catanese J, Dutcher JP, Dorfman HD, et al. Mediastinal osteosarcoma with extension to lungs in a patient treated for Hodgkin’s disease. Cancer. 1988;62:2252.

    Article  PubMed  CAS  Google Scholar 

  225. O’Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010;28:1232.

    Article  PubMed  Google Scholar 

  226. Franklin JG, Paus MD, Pluetschow A, Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin’s disease, with emphasis on second cancer risk. Cochrane Database Syst Rev. 2005;4:CD003187.

    Google Scholar 

  227. De Bruin M, Sparidans J, Van’t Veer MB, et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27:4239.

    Article  PubMed  Google Scholar 

  228. Gervais-Fagnou DD, Girouard C, Laperriere N, et al. Breast cancer in women following supradiaphragmatic irradiation for Hodgkin’s disease. Oncology. 1999;57:224.

    Article  PubMed  CAS  Google Scholar 

  229. Howell SJ, Searle C, Goode V, et al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer. 2009;101:582.

    Article  PubMed  CAS  Google Scholar 

  230. Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010;152:444.

    PubMed  Google Scholar 

  231. Kwong A, Hancock SL, Bloom JR, et al. Mammographic screening in women at increased risk of breast cancer after treatment of Hodgkin’s disease. Breast J. 2008;14:39.

    Article  PubMed  Google Scholar 

  232. Boulheris H, Ron E, Dores GM, et al. Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. Cancer. 2008;113:3153.

    Article  Google Scholar 

  233. Chen YT, Chadburn A, Lee P, et al. Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proc Natl Acad Sci USA. 2010;107:3093.

    Article  PubMed  CAS  Google Scholar 

  234. Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008;111:71.

    Article  PubMed  CAS  Google Scholar 

  235. van der Kaaij MA, Heutte N, Le Stang N, et al. Gonadal function in males after chemotherapy for early-stage Hodgkin’s lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2007;25:2825.

    Article  PubMed  CAS  Google Scholar 

  236. Papadakis V, Vlachopapadoulou E, Van Syckle K, et al. Gonadal function in young patients successfully treated for Hodgkin’s disease. Med Pediatr Oncol. 1999;32:366.

    Article  PubMed  CAS  Google Scholar 

  237. O’Flaherty C, Vaisheva F, Hales BF, et al. Characterization of sperm chromatin quality in testicular cancer and Hodgkin’s lymphoma patients prior to chemotherapy. Hum Reprod. 2008;23:1044.

    Article  PubMed  CAS  Google Scholar 

  238. Fitoussi A, Eghbali H, Tchen N, et al. Semen analysis and cryopreservation before treatment in Hodgkin’s disease. Ann Oncol. 2000;11:679.

    Article  PubMed  CAS  Google Scholar 

  239. van der Kaaij MA, Heutte N, van Echte-Arends J, et al. Sperm quality before treatment in patients with early stage Hodgkin’s lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica. 2009;94:1691.

    Article  PubMed  Google Scholar 

  240. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2005;23:7555.

    Article  PubMed  Google Scholar 

  241. Aisner J, Wiernik PH, Pearl P. Pregnancy outcome in patients treated for Hodgkin’s disease. J Clin Oncol. 1993;11:507.

    PubMed  CAS  Google Scholar 

  242. Falario S, Angrilli F, Fioritoni G. Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma. Leuk Lymphoma. 2008;49:1087.

    Article  CAS  Google Scholar 

  243. Seshadri T, Gook D, Lade S, et al. Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer. 2006;94:1007.

    Article  PubMed  CAS  Google Scholar 

  244. McCullough L, Ng A, Najita J, et al. Breastfeeding in survivors of Hodgkin lymphoma treated with chest radiotherapy. Cancer. 2010;116(20):4866–71.

    Article  PubMed  Google Scholar 

  245. Constine LS, Donaldson SS, McDougall IR, et al. Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease. Cancer. 1984;53:878.

    Article  PubMed  CAS  Google Scholar 

  246. Hancock SL, Cox RS, McDouglass IR. Thyroid disease after treatment of Hodgkin’s disease. N Engl J Med. 1991;325:599.

    Article  PubMed  CAS  Google Scholar 

  247. Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin’s disease. J Clin Oncol. 2007;25:332.

    Article  PubMed  CAS  Google Scholar 

  248. Maule M, Scélo G, Pastore G, et al. Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. J Natl Cancer Inst. 2007;99:790.

    Article  PubMed  Google Scholar 

  249. O’Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010;28:1232.

    Article  PubMed  Google Scholar 

  250. Metzger ML, Hudson MM, Somes GW, et al. White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin’s lymphoma. J Clin Oncol. 2006;24:1516.

    Article  PubMed  Google Scholar 

  251. Schimpff SC, Diggs CH, Wiswell JG, et al. Radiation-related thyroid dysfunction: implications for the treatment of Hodgkin’s disease. Ann Intern Med. 1980;92:91.

    PubMed  CAS  Google Scholar 

  252. De Bruin ML, Dorrestejin LD. van’t Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101:928.

    Article  PubMed  Google Scholar 

  253. Duffey P, Campbell Jr EW, Wiernik PH. Hydrocele following treatment for Hodgkin’s disease. Cancer. 1982;50:305.

    Article  PubMed  CAS  Google Scholar 

  254. Olver IN, Pearl P, Wiernik PH, Aisner J. Small bowel obstruction as a late complication of the treatment of Hodgkin’s disease. Aust NZ J Surg. 1990;60:585.

    Article  CAS  Google Scholar 

  255. Audard V, Zhang SY, Copie-Bergman C, et al. Occurrence of minimal change nephrotic syndrome in classical Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes. Blood. 2010;115:3756.

    Article  PubMed  CAS  Google Scholar 

  256. Horwitz M, Wiernik PH. Pseudoautosomal linkage of Hodgkin’s disease. Am J Hum Genet. 1999;65:1413.

    Article  PubMed  CAS  Google Scholar 

  257. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362:875.

    Article  PubMed  CAS  Google Scholar 

  258. Younes A, Fayad LY, Goy A. Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: improvement of event free survival (EFS) in all international prognostic score (IPS) groups. Blood. 2006;108: Abstract 2742.

    Google Scholar 

  259. Oki Y, Younes A. Does rituximab have a place in treating classic Hodgkin lymphoma? Curr Hematol Malig Rep. 2010;5:135.

    Article  PubMed  Google Scholar 

  260. Mandac I, Kolonic SO. Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin’s lymphoma. J Hematol Oncol. 2010;28:20.

    Article  CAS  Google Scholar 

  261. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85:320.

    PubMed  CAS  Google Scholar 

  262. Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol. 2009;147:97.

    Article  PubMed  CAS  Google Scholar 

  263. Jayanthan A, Howard SC, Trippett T, et al. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma. 2009; 50:1174.

    Article  PubMed  CAS  Google Scholar 

  264. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171.

    Article  PubMed  CAS  Google Scholar 

  265. Keegan TH, Clarke CA, Chang ET, et al. Disparities in survival after Hodgkin lymphoma: a population-based study. Cancer Causes Control. 2009;20(10):1881–92.

    Article  PubMed  Google Scholar 

  266. Appelfeld MM, Cole JF, Pollock SH, et al. The late appearance of chronic pericardial disease in patients treated by radiotherapy for Hodgkin’s disease. Ann Intern Med. 1981;94:338.

    Google Scholar 

  267. Siregar S, de Heer F, van Herwerden LA. Cardiac surgery in patients irradiated for Hodgkin’s lymphoma. Neth Heart J. 2010;18:61.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leukemia Program, Cancer Center, St. Lukes—Roosevelt and Beth Israel Hospitals, New York, NY, 10019, USA

    Peter H. Wiernik M.D.

  2. Department of Hematology, Humanitas Cancer Center, Via Manzoni 56, Rozzano, 20089, Italy

    Monica Balzarotti M.D.

  3. Department of Oncology and Hematology, Istituto Clinico Humanitas, Via A Manzoni 56, Rozzano, 20089, Italy

    Armando Santoro M.D.

Authors
  1. Peter H. Wiernik M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Balzarotti M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Armando Santoro M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter H. Wiernik M.D. .

Editor information

Editors and Affiliations

  1. Beth Israel Hospital, Cancer Center, St. Lukes-Roosevelt Hospital Center, 10th Avenue 1000, New York, 10019, New York, USA

    Peter H. Wiernik

  2. , Department of Hematology, Imperial College of London, Du Cane Road 150, London, W12 0NN, United Kingdom

    John M. Goldman

  3. Continuum Cancer Centers, Department of Medicine, St. Luke's-Roosevelt Hospital Center, 10th Avenue 1000, New York, 10019, New York, USA

    Janice P. Dutcher

  4. , Division of Hematology, Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    Robert A. Kyle

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Wiernik, P.H., Balzarotti, M., Santoro, A. (2013). Diagnosis and Treatment of Hodgkin’s Lymphoma. In: Wiernik, P., Goldman, J., Dutcher, J., Kyle, R. (eds) Neoplastic Diseases of the Blood. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3764-2_45

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3764-2_45

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-3763-5

  • Online ISBN: 978-1-4614-3764-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation